701 hasil
Menampilkan 1–20 · 0,42 detik · RSS
New England Journal of Medicine
Scopus
ISSN 0028-4793 · Massachusetts Medical Society · 701 artikel di indeks
-
Artikel Jurnal
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer
BACKGROUND: The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear. METHODS: In this phase 3, open-label trial, we randomly assigned participants with…
-
Artikel Jurnal
Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes
BACKGROUND: The cardiovascular safety of oral semaglutide, a glucagon-like peptide 1 receptor agonist, has been established in persons with type 2 diabetes and high cardiovascular risk. An assessment of the cardiovascular efficacy of oral semaglutide in persons with type 2 diabetes and…
-
Artikel Jurnal
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes
BACKGROUND: Limited evidence exists to support the simultaneous initiation of sodium-glucose cotransporter-2 inhibitors and finerenone, a nonsteroidal mineralocorticoid receptor antagonist, in persons with chronic kidney disease and type 2 diabetes. METHODS: of body-surface area), albuminuria (a…
-
Artikel Jurnal
Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease
Base editors can correct disease-causing genetic variants. After a neonate had received a diagnosis of severe carbamoyl-phosphate synthetase 1 deficiency, a disease with an estimated 50% mortality in early infancy, we immediately began to develop a customized lipid nanoparticle-delivered…
-
Artikel Jurnal Teks lengkap
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
BACKGROUND: Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether tarlatamab is more effective than chemotherapy in the treatment of patients whose…
-
Artikel Jurnal
Perioperative Chemotherapy or Preoperative Chemoradiotherapy in Esophageal Cancer
BACKGROUND: The best multimodal approach for resectable locally advanced esophageal adenocarcinoma is unclear. An important question is whether perioperative chemotherapy is preferable to preoperative chemoradiotherapy. METHODS: In this phase 3, multicenter, randomized trial, we assigned in a 1:1…
-
Artikel Jurnal
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity
BACKGROUND: Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 diabetes is unknown. METHODS: In this phase 3b, open-label, controlled trial, adult…
-
Artikel Jurnal Teks lengkap
Endovascular Treatment for Stroke Due to Occlusion of Medium or Distal Vessels
BACKGROUND: Endovascular treatment (EVT) of stroke with large-vessel occlusion is known to be safe and effective. The effect of EVT for occlusion of medium or distal vessels is unclear. METHODS: We randomly assigned participants with an isolated occlusion of medium or distal vessels (occlusion of…
-
Artikel Jurnal Teks lengkap
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
BACKGROUND: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy. METHODS: In a phase 3, randomized, controlled trial, we assigned adults with…
-
Artikel Jurnal
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
BACKGROUND: Dual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor may be more effective than GLP-1 receptor agonism alone for treating metabolic dysfunction-associated steatohepatitis (MASH). The efficacy and safety of survodutide (a dual agonist of glucagon receptor and…
-
Artikel Jurnal Teks lengkap
Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair–Deficient Colon Cancer
BACKGROUND: Mismatch repair-deficient (dMMR) tumors can be found in 10 to 15% of patients with nonmetastatic colon cancer. In these patients, the efficacy of chemotherapy is limited. The use of neoadjuvant immunotherapy has shown promising results, but data from studies of this approach are…
-
Artikel Jurnal
Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer
BACKGROUND: Neoadjuvant chemotherapy followed by radical cystectomy is the standard treatment for cisplatin-eligible patients with muscle-invasive bladder cancer. Adding perioperative immunotherapy may improve outcomes. METHODS: In this phase 3, open-label, randomized trial, we assigned, in a 1:1…
-
Artikel Jurnal Teks lengkap
Omalizumab for the Treatment of Multiple Food Allergies
BACKGROUND: Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. METHODS: In this trial, we assessed whether omalizumab, a monoclonal anti-IgE antibody, would be effective and safe as monotherapy in patients…
-
Artikel Jurnal Teks lengkap
Inflammation, Cholesterol, Lipoprotein(a), and 30-Year Cardiovascular Outcomes in Women
BACKGROUND: High-sensitivity C-reactive protein (CRP), low-density lipoprotein (LDL) cholesterol, and lipoprotein(a) levels contribute to 5-year and 10-year predictions of cardiovascular risk and represent distinct pathways for pharmacologic intervention. More information about the usefulness of…
-
Artikel Jurnal Teks lengkap
Alectinib in Resected ALK -Positive Non–Small-Cell Lung Cancer
Background Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant alectinib as compared with chemotherapy in patients with resected ALK -positive NSCLC are lacking…
-
Artikel Jurnal Teks lengkap
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
BACKGROUND: Adjuvant therapy with durvalumab, with or without tremelimumab, may have efficacy in patients with limited-stage small-cell lung cancer who do not have disease progression after standard concurrent platinum-based chemoradiotherapy. METHODS: In a phase 3, double-blind, randomized…
-
Artikel Jurnal Teks lengkap
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
BACKGROUND: Many older adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have a relapse despite having a measurable residual disease (MRD)-negative complete remission with combination chemotherapy. The addition of blinatumomab, a bispecific T-cell engager molecule that is approved…
-
Artikel Jurnal Teks lengkap
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
BACKGROUND: Whether stereotactic body radiotherapy (SBRT) is noninferior to conventionally or moderately hypofractionated regimens with respect to biochemical or clinical failure in patients with localized prostate cancer is unclear. METHODS: We conducted a phase 3, international, open-label…
-
Artikel Jurnal Teks lengkap
Andexanet for Factor Xa Inhibitor–Associated Acute Intracerebral Hemorrhage
BACKGROUND: Patients with acute intracerebral hemorrhage who are receiving factor Xa inhibitors have a risk of hematoma expansion. The effect of andexanet alfa, an agent that reverses the effects of factor Xa inhibitors, on hematoma volume expansion has not been well studied. METHODS: We randomly…
-
Artikel Jurnal Teks lengkap
Cognition and Memory after Covid-19 in a Large Community Sample
BACKGROUND: Cognitive symptoms after coronavirus disease 2019 (Covid-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are well-recognized. Whether objectively measurable cognitive deficits exist and how long they persist are unclear. METHODS: We invited…